Impact Biomedical Inc. has announced a significant merger with Dr. Ashleys Limited, resulting in a newly formed entity that will trade on the NYSE American under the name "Dr Ashleys Limited." This strategic move will see Dr. Ashleys acquire Impact Biomedical through a reverse merger, integrating Impact Biomedical's intellectual property portfolio into Dr. Ashleys' research and development efforts. The merger aims to accelerate the development of innovative pharmaceutical treatments and expand their global reach. Dr. Kanans Visvanats, Director of Dr. Ashleys Limited, emphasized the milestone's importance in bringing groundbreaking therapies to patients worldwide. Frank D. Heuszel, CEO of Impact Biomedical Inc., expressed excitement about the collaboration, highlighting Dr. Ashleys' global reach and resources that will help bring their innovations to market.